Download View press release doc - 79 KB

CONTACTS:
Charles M. Caprariello
Vice President, Corporate Communications
Ranbaxy Inc.
(609) 720-5615
Edwige Buteau
RF Binder Partners Inc.
(212) 994-7517
Anna Wang
Communication and Advocacy Officer
Medicines for Malaria Venture
+41 79 204 2875
Anuj Baveja
RF Binder Partners Inc.
(212) 994-7552
(NOT) FOR IMMEDIATE RELEASE
Promising New Antimalarial Drug Demonstrates Significant Parasite Reduction in Patients
Gurgaon, Haryana, India; Geneva, Switzerland; Washington D.C., U.S. – December 13, 2005 -- Ranbaxy
Laboratories Limited (RLL) and Medicines for Malaria Venture (MMV) announced today that they will provide an
update on the progress and clinical development strategy of a promising, new antimalarial drug, designated RBx
11160, at a tropical disease symposium in Washington, D.C., December 14, 2005. RLL is developing RBx 11160
jointly with the Geneva-based MMV.
RBx 11160 is entering into Phase IIb dose range studies in India, Thailand and Africa very soon after the successful
completion of a Phase IIa Proof of Concept study in October 2005. RBx 11160 is the first synthetic peroxide
antimalarial, and one that could be produced inexpensively and quickly. It thus holds great promise for the millions of
people in 90 countries who are afflicted with the disease. One million people die from malaria every year; the majority
of its victims are children under the age of five and pregnant women in developing countries.
Dr. Nilanjan Saha, Head – Clinical Pharmacology and Development at RLL, will present Ranbaxy’s development
strategy for RBx 11160 at the 54th Annual Meeting of the American Society of Tropical Medicine and Hygiene to be
held in Washington, D.C. December 11-15, 2005 at the Hilton Hotel and Towers. The symposium, titled “RBx
11160/OZ277 The First Synthetic Trioxolane Antimalarial,” is co-chaired by Vijay K. Batra, Ph.D., Head - Generics,
NDDS & Drug Development at RLL, and Dr. J. Carl Craft, Chief Scientific Officer of MMV.
Dr. Brian Tempest, CEO & Managing Director, RLL, said, "Ranbaxy is committed to help save lives from the
worldwide scourge of malaria, and we therefore are doing everything we can to expedite the progress of RBx 11160
through all necessary clinical trials and regulatory reviews. Our goal is to bring this drug to market as quickly as
possible at affordable prices to developing countries, and exchanging information on our progress at symposia like
these helps to facilitate the process and encourage our efforts.”
Page 1 of 4
Prof. Sornchai Looareesuwan, Department of Tropical Medicine, Mahidol University, Bangkok Thailand,
said, “The success, so far, of RBx 11160 in its clinical trials is very encouraging to researchers. We believe
this drug may turn out to be one of the most significant advances in malaria treatment in decades.”
"We've known that artemisinin-based drugs are an effective treatment for malaria, but these naturally
derived drugs are costly to prepare and are beyond the financial reach of millions of malaria victims in poor
countries," said William N. Charman, Ph.D. of Monash University in Australia, another presenter at the
symposium. "RBx 11160 gives these people hope as it provides an impressive anti-malarial effect, but at a
more affordable and lower cost" he said.
As a totally synthetic antimalarial molecule, RBx 11160 could replace Artemisinin, a natural chemical derived from a
scarce and expensive plant, because bulk production of RBx 11160 is expected to be faster and more economical
compared with the existing, agriculture-based Artemisinin derivatives, currently grown in the fields of China. Being a
drug with short half-life, RBx 11160 will be combined with another long-acting drug, piperaquine phosphate (PQP), to
comply with the current World Health Organization (WHO) guidelines for development of new anti-malarial
compounds.
“We desperately need more and better ammunition to fight this persistent killer,” said Dr. J Carl Craft, CSO of MMV,
“MMV is proud to be working on this exciting project with Ranbaxy. The progress made so far signifies how effective
partnerships can accelerate drug development for neglected diseases.”
At the symposium, Dr. Saha will outline the product development strategy for RBx 11160 and report on its
encouraging progress to date. Highlights of his presentation include:

RBx 11160 has been found to be well tolerated at up to 600 mg administered as a single dose and at up to 200
mg administered as single daily dose for seven days in healthy young subjects. This finding emerged from
Phase I clinical trials in healthy young and elderly volunteers conducted at the Guy’s Drug Research Unit,
Quintiles, U.K.

A proof-of-concept (POC) study has recently been successfully completed in Bangkok, Thailand in 72 patients
suffering from acute uncomplicated P. falciparum malaria.

A dose ranging study is to be inititated soon to evaluate the effect of RBx 11160 in more than 250 patients
suffering from acute uncomplicated P. falciparum malaria. These patients will be enrolled at clinical trial centers
in Thailand, India, Tanzania and Zanzibar.

Per WHO guidelines on development of new anti-malarials, the short and rapidly acting RBx 11160 has to be
combined with a long acting molecule when used in patients. Piperaquine phosphate (PQP) has been chosen as
the partner molecule. Safety and tolerability date of a wide range of doses of PQP will be generated in a wellcontrolled Phase I clinical trial expected to begin in Switzerland in 2006.
Page 2 of 4

Simultaneously, Ranbaxy will start work on developing a parenteral formulation of RBx 11160 for the treatment
of severe and complicated P.falciparum malaria. Clinical development is expected to begin once an
Investigational New Drug application on the parenteral formulation is filed in 2006.

Ranbaxy expects to file a New Drug Application (NDA) for a combination of RBx 11160 and PQP in early 2009.
This product is intended to be made available for the treatment of acute uncomplicated P. falciparum malaria.

Once approved, Ranbaxy plans to make the drug available in malaria-affected regions of Asia, Africa and South
America.

Since supply of RBx 11160 would not depend on agricultural production necessary for artemisinin derivatives,
the commercial production of RBx 11160 and PQP is likely to be in a range that would allow Ranbaxy to supply
the treatment at a humanitarian cost.
About Ranbaxy Laboratories Limited
Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical
company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and
patients across geographies.
Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress
in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary
"platform technologies", resulting in a number of products under development. The Company is serving its customers
in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground
operations in 46 countries and manufacturing operations in 7 countries. For more information, please visit
www.ranbaxy.com
About Medicines for Malaria Venture
Medicines for Malaria Venture (MMV) is a non-profit organisation dedicated to reducing the burden of malaria in
disease-endemic countries by discovering, developing and delivering new affordable antimalarial drugs through
effective public-private partnership. After five years of operation, MMV is managing the largest-ever portfolio of
malaria drug research with more than 20 projects in different stages of drug research and development. MMV’s goal
is to register at least one new antimalarial before 2010 and maintain a sustainable pipeline of antimalarials to meet
the needs of the 2.4 billion people at risk of this deadly disease. For further information please consult
http://www.mmv.org
###
Editors note:
“RBx 11160/0Z277: The First Synthetic Trioxolane Antimalarial”
3:45 – 5:30 pm, December 14, 2005
54th Annual Meeting of The American Society of Tropical Medicine and Hygiene, Hilton Hotel and
Towers, Washington D.C.
J. Carl Craft, Medicines for Malaria Venture (MMV), Symposium Organizer, Co-Chair
Vijay K. Batra, Ranbaxy Laboratories Ltd., Co-Chair
Sergio Wittlin, Swiss Tropical Institute, Basel
“Activity Profile of Synthetic Trioxolane of Anti-Malarial
William N. Charman, Monash University, Melbourne, Australia
“Selection of Synthetic Trioxolane Candidate for Development”
Page 3 of 4
Tim Mant, Guy’s Drug Research Unit, London
“Human Safety and Pharmacokinetics of RBX 11160/0Z277”
Nilanjan Saha, Ranbaxy Laboratories Ltd.
“Clinical Development Strategy for RBX 11160/0Z277”
Page 4 of 4